Mixed trend on the daily chart: above its 200-day average, below its 50-day · 50-day above the 200-day · SuperTrend down since Sep 10 · below the Ichimoku cloud · RSI 39 · MACD below its signal
| 9.31 | Previous month high | +31.13% |
| 9.31 | 52-week high | +31.13% |
| 8.06 | R3 (classic) | +13.57% |
| 7.84 | R2 (classic) | +10.38% |
| 7.83 | Previous week high | +10.28% |
| 7.61 | Previous day high | +7.18% |
| 7.59 | Previous month low | +6.90% |
| 7.47 | R1 (classic) | +5.19% |
| 7.24 | Pivot | +2.00% |
| 7.10 | Price now | |
| 7.01 | Previous day low | −1.20% |
| 7.01 | Previous week low | −1.20% |
| 6.87 | S1 (classic) | −3.19% |
| 6.65 | S2 (classic) | −6.38% |
| 6.28 | S3 (classic) | −11.57% |
| 3.86 | 52-week low | −45.63% |
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $2.1M | 0.00% | 302.57K | −11% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a EOLS trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 1, 2026 | Moatazedi DavidChief Executive Officer | Sale at price 9.04 per share. | 105.1K | $950.02K |
| Mar 19, 2026 | Avelar Rui L.Officer | Sale at price 4.75 per share. | 3.1K | $14.81K |
| Mar 19, 2026 | Moatazedi DavidChief Executive Officer | Sale at price 4.75 per share. | 13.7K | $64.93K |
| Mar 16, 2026 | Avelar Rui L.Officer | Sale at price 4.89 per share. | 30K | $146.63K |
| Mar 16, 2026 | Moatazedi DavidChief Executive Officer | Sale at price 4.89 per share. | 116.7K | $570.56K |
| Mar 15, 2026 | Avelar Rui L.Officer | — | 8.8K | — |
| Mar 15, 2026 | Moatazedi DavidChief Executive Officer | — | 67.5K | — |
| Feb 16, 2026 | Avelar Rui L.Officer | Stock Award(Grant) at price 0.00 per share. | 94.9K | — |
| Feb 16, 2026 | Parschauer Karah HerdmanDirector | Stock Award(Grant) at price 0.00 per share. | 45.6K | — |
| Feb 16, 2026 | Moatazedi DavidChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 313.2K | — |
| Feb 16, 2026 | Malik VikramDirector | Stock Award(Grant) at price 0.00 per share. | 45.6K | — |
| Feb 16, 2026 | Stewart BradyDirector | Stock Award(Grant) at price 0.00 per share. | 45.6K | — |
| Feb 16, 2026 | Mitchell TatjanaChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 121.5K | — |
| Feb 16, 2026 | Gill David N.Director | Stock Award(Grant) at price 0.00 per share. | 45.6K | — |
| Feb 16, 2026 | White Albert G IiiDirector | Stock Award(Grant) at price 0.00 per share. | 45.6K | — |
| Dec 21, 2025 | Avelar Rui L.Officer | Sale at price 7.15 per share. | 2.3K | $16.17K |
| Dec 21, 2025 | Moatazedi DavidChief Executive Officer | Sale at price 7.15 per share. | 10.5K | $75.36K |
| Sep 7, 2025 | Mitchell TatjanaChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 104.6K | — |
| Aug 21, 2025 | Yamagishi-Dressler TomokoOfficer | Sale at price 7.51 per share. | 5.7K | $42.97K |
| Aug 14, 2025 | Stewart BradyDirector | Purchase at price 6.82 per share. | 30K | $204.49K |
TimeframesDown on the hourly, daily and monthly, mixed on the weekly.
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
pulling back under the 21 EMA
under a falling 21 EMA, 21 under 50
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -29.5 | -8.3 | -4.4 | 31.1 | 21.7 | 5.8 | -15.9 | 55.7 | -12.0 | -11.3 | +6.8% | ||
| 2025 | 26.5 | 4.4 | -17.5 | -5.2 | -19.4 | 0.2 | -3.1 | -14.5 | -19.5 | 5.2 | 10.8 | -7.1 | −39.8% |
| 2024 | 20.5 | 16.9 | -5.6 | -15.9 | 9.9 | -16.1 | 14.5 | 27.9 | 2.0 | 0.7 | -16.1 | -19.4 | +4.8% |
| 2023 | 38.3 | -12.7 | -6.7 | 3.3 | 3.5 | -19.7 | 37.8 | -1.3 | -7.6 | -16.8 | 24.6 | 11.2 | +40.2% |
| 2022 | 14.0 | 23.3 | 22.6 | -0.3 | 15.3 | -10.1 | 6.3 | -22.1 | -16.2 | 6.3 | -15.4 | 3.7 | +15.4% |
| 2021 | 101.2 | 79.1 | 7.3 | -29.9 | 18.8 | 16.9 | -14.5 | -2.0 | -28.1 | 2.6 | -29.2 | 17.5 | +93.8% |
| 2020 | -15.9 | -16.0 | -51.7 | 0.2 | 9.9 | 16.0 | -38.5 | 18.4 | 1.3 | -22.5 | 23.1 | -9.9 | −72.4% |
| 2019 | 37.4 | 61.7 | -14.6 | 8.0 | -44.2 | 7.5 | 21.4 | -2.9 | -9.4 | 2.1 | -12.3 | -13.0 | +2.3% |
| 2018 | -25.3 | -24.1 | 257.7 | 14.2 | -29.8 | 30.2 | -27.2 | -20.4 | 0.9 | -20.5 | −1.6% |
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Buy / hold / sell counts